Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 3 1

Status

Completed 25Recruiting 8Unknown 7Terminated 4Not yet recruiting 2Active not recruiting 2

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 7

Sponsor

Cancer Type

Gynecologic 3CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 84Ovarian Neoplasms 35Breast Neoplasms 32Lung Neoplasms 28Uterine Cervical Neoplasms 18Triple Negative Breast Neoplasms 15Fallopian Tube Neoplasms 15Carcinoma, Ovarian Epithelial 15Small Cell Lung Carcinoma 13Squamous Cell Carcinoma of Head and Neck 10Neuroblastoma 10Esophageal Neoplasms 10Esophageal Squamous Cell Carcinoma 8Central Nervous System Neoplasms 8Recurrence 7Head and Neck Neoplasms 6Endometrial Neoplasms 6Retinoblastoma 5Neoplasm Metastasis 5Brain Neoplasms 5Adenocarcinoma of Lung 5Neoplasms 4Melanoma 4Carcinoma, Squamous Cell 4Testicular Neoplasms 3Oligodendroglioma 3Medulloblastoma 3Lymphoma, Large B-Cell, Diffuse 3Hodgkin Disease 3Glioblastoma 3

Interventions

Cyclophosphamide 17fludarabine 13Dexamethasone 12Cisplatin 12Rituximab 10Gemcitabine 9Paclitaxel 8Bendamustine Hydrochloride 8Lenalidomide 7Decitabine 7Cytarabine 7Carboplatin 7fludarabine phosphate 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Etoposide 6Bortezomib 6Radiotherapy 5Injections 5Azacitidine 5camrelizumab 4apatinib 4Valproic Acid 4Thalidomide 4Procarbazine 4Oxaliplatin 4Drug Therapy 4Bevacizumab 4Antilymphocyte Serum 4venetoclax 3pomalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Unknown × Recurrence × Carboplatin × Clear all
NCT04739670 2024-03-01

BELLA

Peter MacCallum Cancer Centre, Australia

Phase 2 Unknown
31 enrolled
Breast

Recurrence, Triple Negative Breast Neoplasms

NCT05715840 2023-02-08

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3 Unknown
368 enrolled

Recurrence

NCT03467178 2021-09-05

MITO29

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Unknown
119 enrolled

Recurrence

NCT01650376 2018-03-23

Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer

Swedish Medical Center

Phase 1/2 Unknown
52 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence, Uterine Neoplasms

NCT02492503 2015-07-08

Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix

All India Institute of Medical Sciences

Phase 1/2 Unknown
40 enrolled
Gynecologic

Uterine Cervical Neoplasms, Recurrence

NCT01388621 2013-08-20

PROVE

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 2 Unknown
140 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT00635557 2011-03-25

Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme

Myrexis Inc.

Phase 1/2 Unknown
30 enrolled
CNS

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡